Financial Performance - The company reported a basic earnings per share of 1.13 yuan for 2024, an increase of 9.71% compared to 1.03 yuan in 2023 [1] - The net profit for 2024 was 11.44 billion yuan, reflecting a growth of 10.32% from 10.37 billion yuan in 2023 [1] - The total operating revenue reached 56.98 billion yuan, marking a 13.01% increase from 50.42 billion yuan in the previous year [1] - The return on equity (ROE) decreased slightly to 16.79% from 17.28% in 2023 [1] Shareholder Structure - The top ten unrestricted shareholders collectively hold 43,236.73 million shares, accounting for 49.01% of the circulating shares, with a decrease of 1,033.76 million shares compared to the previous period [1] - Xu Zhou Enhua Investment Co., Ltd. remains the largest shareholder with 32,009.63 million shares, representing 36.30% of the total share capital [2] - Other notable shareholders include Zhang Xu with 2,181.78 million shares and Hong Kong Central Clearing Limited with 1,404.66 million shares, both showing a decrease in holdings [2] Dividend Distribution - The company announced a dividend distribution plan of 3.6 yuan per share (including tax) [3]

江苏恩华药业股份有限公司 2024年度独立董事述职报告 2024年度，本人作为江苏恩华药业股份有限公司（以下简称"公司"）第六届董事会的 独立董事，根据《中华人民共和国公司法》（ 以下简称"《公司法》"）、《上市公司独立 董事管理办法》《深圳证券交易所上市公司自律监管指引第1号——主板上市公司规范运作》 等相关法律法规的规定和《公司章程》《独立董事工作制度》等的要求，严格保持独立董事 的独立性和职业操守，诚信、勤勉、尽责、忠实地履行职责，依法合规、谨慎负责地行使公 司所赋予独立董事的权力，积极出席公司相关会议并认真审议各项议案，切实维护公司及全 体股东特别是中小股东的利益。现将2024年度履行独立董事职责情况报告如下： 一、独立董事的基本情况 （一）个人履历及专业背景 本人印晓星，博士研究生，现任徐州医科大学教授、药理学博士生导师。现为教育部高 等学校药学类专业教学指导委员会委员、江苏省理学2类研究生教育指导委员会主任委员、江 苏省药理学会副理事长、江苏省药理学会新药临床前药理专业委员会主任委员。主持国家自 然科学基金、江苏省自然科学基金等多项，以通讯作者发表SCI收录论文90余篇，以第一完成 人申请专利12 ...

江苏恩华药业股份有限公司 2024年度独立董事述职报告 2024年度，本人作为江苏恩华药业股份有限公司（以下简称"公司"）第六届董事会的 独立董事，根据《中华人民共和国公司法》（ 以下简称"《公司法》"）、《上市公司独立 董事管理办法》《深圳证券交易所上市公司自律监管指引第1号——主板上市公司规范运作》 等相关法律法规的规定和《公司章程》《独立董事工作制度》等的要求，严格保持独立董事 的独立性和职业操守，诚信、勤勉、尽责、忠实地履行职责，依法合规、谨慎负责地行使公 司所赋予独立董事的权力，积极出席公司相关会议并认真审议各项议案，切实维护公司及全 体股东特别是中小股东的利益。现将2024年度履行独立董事职责情况报告如下： 一、独立董事的基本情况 （一）个人履历及专业背景 本人李玉兰，大专学历，高级会计师。曾任徐州市财政局商贸科副科长、商贸科科长、 徐州市财政局副局长、徐州市财政局调研员等职；具有多年从事企业财务管理、财政财务管 理方面的工作经验。2022年4月至今，担任公司独立董事。 （二）独立性情况说明 报告期内，本人任职符合《上市公司独立董事管理办法》规定的独立性要求，不存在影 响独立性的情况。 二、独立董 ...

江苏恩华药业股份有限公司 江苏恩华药业股份有限公司董事会 2025年3月28日 董事会对独立董事独立性评估的专项意见 根据证监会《上市公司独立董事管理办法》、深圳证券交易所《股票上市规则》《深圳证券 交易所上市公司自律监管指引第1号——主板上市公司规范运作》等相关规定要求，江苏恩华 药业股份有限公司（以下简称"公司"）董事会就公司在任独立董事印晓星、李玉兰、陈国祥的 独立性情况进行评估并出具如下专项意见： 经核查独立董事印晓星、李玉兰、陈国祥的任职经历以及签署的相关自查文件，公司董事 会认为上述人员未在公司担任除独立董事以外的任何职务，也未在公司主要股东单位及其附属 企业担任任何职务，与公司以及主要股东之间不存在利害关系或其他可能妨碍其进行独立客观 判断的关系，不存在影响独立董事独立性的情况。因此，公司独立董事符合《上市公司独立董 事管理办法》《深圳证券交易所上市公司自律监管指引第1号——主板上市公司规范运作》中对 独立董事独立性的相关要求。 ...

江苏恩华药业股份有限公司 2024年度独立董事述职报告 2024年度，本人作为江苏恩华药业股份有限公司（以下简称"公司"）第六届董事会的 独立董事，根据《中华人民共和国公司法》（ 以下简称"《公司法》"）、《上市公司独立 董事管理办法》《深圳证券交易所上市公司自律监管指引第1号——主板上市公司规范运作》 等相关法律法规的规定和《公司章程》《独立董事工作制度》等的要求，严格保持独立董事 的独立性和职业操守，诚信、勤勉、尽责、忠实地履行职责，依法合规、谨慎负责地行使公 司所赋予独立董事的权力，积极出席公司相关会议并认真审议各项议案，切实维护公司及全 体股东特别是中小股东的利益。现将2024年度履行独立董事职责情况报告如下： 一、独立董事的基本情况 （一）个人履历及专业背景 本人陈国祥，研究生学历，高级会计师。曾任徐钢总厂副厂长和党委副书记，徐州光大 新兴铸管有限公司总经理和党委书记，圣戈班（徐州）管道公司销售总监，圣戈班管道系统 有限公司中国区副总裁，商务运行总监，徐州市人大代表。现任徐州市国资委国有企业兼职 外部董事。2022年4月至今，担任公司独立董事。 （二）独立性情况说明 报告期内，本人任职符合《上市公司 ...

江苏恩华药业股份有限公司 2024年度独立董事述职报告 2024年度，本人作为江苏恩华药业股份有限公司（以下简称"公司"）第六届董事会的 独立董事，根据《中华人民共和国公司法》（ 以下简称"《公司法》"）、《上市公司独立 董事管理办法》《深圳证券交易所上市公司自律监管指引第1号——主板上市公司规范运作》 等相关法律法规的规定和《公司章程》《独立董事工作制度》等的要求，严格保持独立董事 的独立性和职业操守，诚信、勤勉、尽责、忠实地履行职责，依法合规、谨慎负责地行使公 司所赋予独立董事的权力，积极出席公司相关会议并认真审议各项议案，切实维护公司及全 体股东特别是中小股东的利益。现将2024年度履行独立董事职责情况报告如下： 一、独立董事的基本情况 （一）个人履历及专业背景 本人王广基，中国工程院院士、原中国药科大学副校长。现任江苏省药物代谢动力学重 点实验室主任，国家科技部临床前药代动力学研究平台主任，国家中医药管理局中药复方药 代动力学方法重点实验室主任，任中国药理学会制药工业专业委员会主任委员，江苏省药理 学会理事长。获国家科学技术进步二等奖4项、部省级科技进步一等奖4项；获2012年何梁何 利基金科学与技术 ...

Financial Performance - The company's operating revenue for 2024 reached ¥5,697,633,044.59, representing a 13.01% increase compared to ¥5,041,504,467.27 in 2023[6]. - Net profit attributable to shareholders for 2024 was ¥1,143,564,427.44, up 10.28% from ¥1,036,918,058.61 in 2023[6]. - The basic earnings per share for 2024 increased to ¥1.13, a rise of 9.71% from ¥1.03 in 2023[6]. - Total assets at the end of 2024 amounted to ¥8,440,005,655.95, reflecting a 15.17% growth from ¥7,328,195,368.67 at the end of 2023[6]. - Operating profit reached ¥1,336,573,612.01, while total profit amounted to ¥1,296,688,433.42, reflecting increases of 13.04% and 10.96% respectively compared to the previous year[49]. - The company achieved a total revenue of ¥5,697,633,044.59 for the fiscal year 2024, representing a year-on-year growth of 13.01%[49]. - The industrial segment contributed ¥4,823,256,135.4, accounting for 84.65% of total revenue, with a year-on-year growth of 14.29%[81]. - Domestic sales amounted to ¥5,614,741,828.0, which is 98.55% of total sales, reflecting a 13.04% increase from the previous year[82]. - International sales surged by 162.53% to ¥23,285,928.63, up from ¥8,869,818.05 in 2023[82]. - The gross profit margin for the industrial segment was 82.77%, with a year-on-year increase of 0.68%[82]. Dividend and Shareholder Returns - The company plans to distribute a cash dividend of 3.60 CNY per 10 shares to all shareholders, based on a total of 1,016,176,792 shares[3]. - The cash dividend amount for the reporting period is 365,823,645.12 CNY, with a per-share dividend of 3.60 CNY[167]. - The total distributable profit for the parent company is 5,629,861,031.98 CNY, with the cash dividend accounting for 100% of the profit distribution[167]. - The company has not made any adjustments to its cash dividend policy during the reporting period, adhering strictly to the established policy[167]. - The company plans to distribute a cash dividend of 3.60 CNY per 10 shares, totaling approximately 365,823,645.12 CNY, which represents 31.99% of the net profit attributable to shareholders for the year 2024[169]. Research and Development - The company is expected to continue focusing on innovation and R&D in response to the pressures from volume-based procurement policies[30]. - The company increased its R&D investment in innovative drugs, with a total expenditure of 721 million yuan, representing a 17.48% increase compared to the previous year[42]. - There are currently over 70 ongoing research projects, including 14 innovative drug projects, with 1 project having completed Phase III clinical trials[42]. - The company applied for 50 invention patents and received 19 authorized patents, including 10 overseas patents[43]. - The company has established a leading R&D platform for high-end drug delivery systems, addressing issues such as patient compliance and addiction[54]. - The company is actively promoting product sales and enhancing business development collaborations in the CNS therapeutic area[43]. Market Position and Strategy - The company is positioned in the pharmaceutical industry, which is experiencing rapid growth due to increasing health demands and an aging population[29]. - The company is a key producer and seller of central nervous system drugs in China, with a unique focus on R&D and production in this field[35]. - The company is the only listed enterprise in China dedicated to the R&D and production of central nervous system drugs, providing a competitive edge[35]. - The company aims to become a leading manufacturer and supplier of central nervous system drugs in China and a significant global production base by 2025[114]. - The company is focusing on unmet clinical needs in the central nervous system field, aligning with national health strategies and policies[51]. Challenges and Risks - The company faces challenges from ongoing healthcare reforms and policies aimed at controlling medical costs, which may impact profitability[30]. - The company must invest substantial funds annually in drug research and development, with the risk of extended development cycles due to stricter national regulations[125]. - Environmental risks are present due to potential pollution from wastewater and waste gas during production, which could affect surrounding communities[125]. - The company faces risks from industry policy changes, including drug approval, quality supervision, and medical insurance cost control, which could significantly impact future development[125]. Corporate Governance and Management - The company has established a long-term mechanism to prevent major shareholders from occupying company funds, ensuring the protection of shareholder rights[132]. - The board of directors consists of four independent directors, exceeding one-third of the total board, ensuring compliance with governance standards[132]. - The company has a complete and independent financial management system, ensuring no interference from controlling shareholders in financial decisions[138]. - The company actively engages in charitable activities, enhancing its social image and fulfilling corporate social responsibilities[135]. - The company has established a transparent performance evaluation and incentive mechanism for directors, supervisors, and managers, ensuring compliance with legal regulations[136]. Environmental Management - The company has established a comprehensive environmental management system and has passed ISO 14001 certification, complying with various environmental standards[187]. - The company invested approximately 5.6 million yuan in 2022 to upgrade its wastewater pre-treatment system, resulting in improved operational stability and reduced use of hazardous chemicals[192]. - The company’s wastewater treatment system has a capacity of 600t/d, with all monitoring results indicating compliance with discharge standards[192]. - The company’s air pollution control system was upgraded in 2021, adding four new systems to improve overall efficiency[193]. - The company allocated approximately 12.34 million yuan for environmental protection and equipment upgrades during the reporting period[198].

证券代码：002262 证券简称：恩华药业 公告编号：2025-005 江苏恩华药业股份有限公司 关于收到1类化学药品《药物临床试验批准通知书》的公告 本公司及董事会全体人员保证公告内容真实、准确和完整，并对公告中的虚假记载、误导 性陈述或者重大遗漏承担责任。 江苏恩华药业股份有限公司（以下简称"公司"）于近日收到国家药品监督管理局（以下 简称"药监局"）核准签发的1类化学药品NH140068片4个规格的《药物临床试验批准通知 书》，并将于近期开展临床试验。现将相关情况公告如下： 一、药品基本情况 药品名称：NH140068片 受理号：CXHL2500032；CXHL2500033；CXHL2500034；CXHL2500035 剂型：片剂 注册分类：化学药品第1类 规格：0.5 mg，1.5 mg，5 mg，20 mg 申请事项：临床试验 申请人：江苏恩华药业股份有限公司 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，2025年1月8日受 理的NH140068片符合药品注册的有关要求，同意本品开展用于精神分裂症的临床试验。 特此公告。 江苏恩华药业股份有限公司 董事会 二、药物的其他情况 N ...

人民财讯3月24日电，恩华药业(002262)3月24日晚间公告，公司于近日收到国家药监局核准签发的1类 化学药品NH140068片4个规格的《药物临床试验批准通知书》，并将于近期开展临床试验。 临床前试验结果表明，它可以激动多巴胺、5-羟色胺和痕量胺的相关受体，具有改善精神分裂症阳性和 阴性症状且副作用小的潜力。 NH140068是一款适于口服的多种神经递质受体激动剂，为新一代治疗精神分裂症的创新药。 ...

Summary of the Conference Call on Enhua Pharmaceutical Company Overview - Enhua Pharmaceutical is a leading company in the central nervous system sector in China, focusing on anesthetics, psychiatric, and neurological drugs. The company has a clear and stable ownership structure and strong production capabilities, actively engaging in internet healthcare through its "Good Mood" platform [3][9]. Industry Insights - The anesthetic drug industry is characterized by high barriers to entry and high market concentration, with the top eight companies holding approximately 75% of the market share. The industry is expected to remain competitive among existing players for the next 5-10 years [5]. - Anesthetic drug usage is closely linked to the number of hospitalized patients and surgical procedures, which have shown stable growth in recent years, contributing to a double-digit growth in the anesthetic drug market [8]. Financial Performance and Projections - Enhua Pharmaceutical's net profit is expected to grow at an annual rate of 15% to 20% from 2024 to 2026, driven by its core anesthetic business and new products like TRV130 [3][15]. - The company's anesthetic business revenue increased significantly, accounting for 54% of total revenue in 2023, with a gross margin of 88.32%. This has led to an overall gross margin increase from 46% in 2016 to approximately 73% [10]. Regulatory Environment - The government has established clear pricing guidelines for anesthetic and psychiatric drugs, which are generally not included in national centralized procurement. This regulatory stability is expected to continue [6][7]. Product Development and Market Position - Enhua has a diverse product line, including new products like TRV130, which is expected to enhance its market position in the pain management sector. The company is also expanding into the sleep disorder market through its newly established sleep division [12][13][14]. - The company has over 70 projects in development, with significant investments in R&D, exceeding 600 million yuan in 2023, marking a 24% increase year-on-year [14]. Risks and Challenges - While centralized procurement policies have negatively impacted some of Enhua's products, the revenue from these products has decreased to around 5%, reducing future performance volatility. The company is also focusing on high-growth prescription products that are not subject to procurement policies [11]. Valuation and Investment Recommendation - Enhua Pharmaceutical's current market capitalization is approximately 23 billion yuan, with a projected P/E ratio of 10 to 16 for 2025, indicating a favorable valuation. Analysts recommend a focus on the company due to its strong growth prospects and stable market position [3][15].